Panel says NSAID labels should not change

Share this article:

An FDA advisory panel said naproxen should not get a heart-friendly label that would indicate it may have a cardiovascular edge over other drugs in its drug class. Medpage Today reports the advisory panel voted 16-9 against a new label, saying there was insufficient evidence to support a change.

The "no" vote does not mean panelists do not think drugs like Aleve may have an edge over other medications. “If I were forced to bet on what the truth is, my bet would be that naproxen is safer,” Susan Ellenberg told the Associated Press.

The panel's decision followed two days of discussions which were prompted by more than 700 studies finding fewer heart problems with OTC and prescribed naproxen compared to other NSAIDs.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.